Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor Grade And Progesterone Receptor Status In Predicting Benefit Of Chemotherapy In High Genomic Risk Breast Cancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor Grade And Progesterone Receptor Status In Predicting Benefit Of Chemotherapy In High Genomic Risk Breast Cancer.

Related Experiment Video

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K

Tumor grade and progesterone receptor status in predicting benefit of chemotherapy in high genomic risk breast cancer.

Ke Liu1, Gui-Ping Chen2, Xue-Qin Chen1

  • 1Xiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.

Expert Review of Anticancer Therapy
|August 17, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

High tumor grade and progesterone receptor-negative status predict a high 21-gene recurrence score (RS) in breast cancer patients. Chemotherapy benefits high-risk RS patients, but not those with specific poor prognostic factors.

Keywords:
Breast cancerPRchemotherapyrecurrence score

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.5K

Related Experiment Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.5K

Area of Science:

  • Oncology
  • Genomics
  • Biostatistics

Background:

  • The 21-gene recurrence score (RS) assay is a valuable tool for guiding breast cancer treatment decisions.
  • However, the cost of the RS assay limits its accessibility for all eligible patients.
  • Identifying clinicopathological factors associated with high-risk RS is crucial for optimizing test utilization.

Purpose of the Study:

  • To identify clinicopathological factors associated with a high-risk 21-gene recurrence score (RS) in early-stage, node-negative, estrogen receptor-positive breast cancer.
  • To determine if these clinicopathological factors correlate with the benefit of chemotherapy in patients with high-risk RS.

Main Methods:

  • Retrospective analysis of 74,605 early-stage, node-negative, estrogen receptor-positive breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Oncotype DX database.
tumor grade
  • Statistical analysis to identify associations between clinicopathological variables (tumor grade, progesterone receptor status) and high-risk RS.
  • Evaluation of chemotherapy's impact on breast cancer-specific survival and overall survival in different risk subgroups.

    • Main Results:

    • Higher tumor grade and progesterone receptor-negative (PR Neg) status were significantly associated with a higher likelihood of a high-risk RS (p < 0.001).
    • Patients with PR Neg/poorly differentiated (G3) tumors had the highest proportion of high-risk RS (80.1%).
    • Chemotherapy improved survival in the high-risk RS cohort (p = 0.010 for breast cancer-specific survival, p < 0.001 for overall survival).
    • No significant survival benefit from chemotherapy was observed in patients with PR Neg/G3 disease or other specific subgroups after stratification by grade and PR status (all p ≥ 0.05).

    Conclusions:

    • Clinicopathological factors, specifically higher tumor grade and progesterone receptor-negative status, can help identify early-stage breast cancer patients likely to have a high-risk 21-gene recurrence score.
    • While the 21-gene RS assay is pivotal for treatment decisions, these factors may aid in refining patient selection for testing, considering economic implications.
    • Chemotherapy offers survival benefits for high-risk RS patients, but not for those with PR Neg/G3 disease, highlighting the need for personalized treatment strategies.